Skip to main content
. 2013 Feb 20;8(2):e56919. doi: 10.1371/journal.pone.0056919

Figure 3. Kaplan-Meier survival analysis of Aur-A and Ki-67 expression in TNBC patients (n = 122).

Figure 3

(A) TNBC patients with high expression of both Aur-A and Ki-67 showed an inferior overall survival (P<0.001), and (B) progression-free survival (P<0.001), compared with both Aur-A and Ki-67 low expression. The median survival time for patients with high expression of both Aur-A and Ki-67 VS. low expression of both Aur-A and Ki-67 were 32.5 months VS. 110.0 months for OS (P<0.001), and 21.8 months VS. 100.0 months for PFS (P<0.001), respectively.